Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter ( ASBT ) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Apical Sodium-Dependent Bile Acid Transporter
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。